A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7000 participants.

Also called NCT07753993

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 7,000 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07753993
  • EU CT 2025-523994-41-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Indonesia, Israel, Italy, Japan, Malaysia, Mexico, Norway, Peru, Philippines, Poland, Romania, Serbia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, United Arab Emirates, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07753993. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-21 (actual); primary completion 2030-10-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
Acronym
Elevate-CKD
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07753993
Content hash
bd2cc2d7a6465119e1dfad0f8e67815a6f9d32f501feed8867a618882c79530a